Although initially approved against ALK fusions in patients with non-small cell lung cancer (NSCLC) [103], crizotinib, another small-molecule kinase inhibitor was evaluated on NTRK-mediated cancers with the first case being a patient with NSCLC harboring the MPRIP–NTRK1 fusion [22]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.